Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$17.10 -1.2%	$17.97	$13.50 ▼ $25.67	$4.08B	0.38	3.13 million shs	1.90 million shs
AKRO Akero Therapeutics	$48.29 +0.7%	$51.59	$21.34 ▼ $58.40	$3.86B	-0.28	1.41 million shs	534,807 shs
SYRE Spyre Therapeutics	$16.78 +2.6%	$16.18	$10.91 ▼ $40.26	$1.01B	2.82	612,350 shs	688,310 shs
ZLAB Zai Lab	$33.99 +1.5%	$36.38	$17.30 ▼ $44.34	$3.78B	1.03	972,200 shs	526,462 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	-0.80%	+0.58%	+0.99%	-14.19%	-3.51%
AKRO Akero Therapeutics	+0.74%	-0.75%	-6.68%	-2.08%	+79.32%
SYRE Spyre Therapeutics	+1.49%	-6.03%	0.00%	+8.49%	-38.74%
ZLAB Zai Lab	-5.47%	-5.98%	-3.35%	+3.08%	+96.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	4.3622 of 5 stars	3.7	3.0	0.0	3.7	2.5	3.1
AKRO Akero Therapeutics	3.9422 of 5 stars	3.5	2.0	4.7	3.3	0.8	0.0
SYRE Spyre Therapeutics	2.8596 of 5 stars	3.6	2.0	0.0	2.6	2.5	0.6
ZLAB Zai Lab	2.7997 of 5 stars	3.4	2.0	0.0	3.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	61.79% Upside
AKRO Akero Therapeutics	3.00	Buy	$81.57	68.92% Upside
SYRE Spyre Therapeutics	3.29	Buy	$53.40	218.24% Upside
ZLAB Zai Lab	2.83	Moderate Buy	$57.22	68.34% Upside

Current Analyst Ratings Breakdown

Latest SYRE, ADMA, ZLAB, and AKRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	ZLAB Zai Lab	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $69.00
8/6/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
8/4/2025	AKRO Akero Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/4/2025	AKRO Akero Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$76.00
6/30/2025	ZLAB Zai Lab	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$73.00 ➝ $75.00
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.57	$0.53 per share	32.22	$1.67 per share	10.24
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$12.82 per share	N/A
SYRE Spyre Therapeutics	$890K	1,138.78	N/A	N/A	$4.97 per share	3.38
ZLAB Zai Lab	$398.99M	9.46	N/A	N/A	$7.13 per share	4.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.86	19.88	24.78	N/A	44.06%	41.01%	28.47%	11/6/2025 (Estimated)
AKRO Akero Therapeutics	-$252.06M	-$2.00	N/A	N/A	N/A	N/A	-15.84%	-14.59%	N/A
SYRE Spyre Therapeutics	-$208.02M	-$3.40	N/A	N/A	N/A	N/A	-71.30%	-38.69%	11/6/2025 (Estimated)
ZLAB Zai Lab	-$257.10M	-$2.04	N/A	N/A	N/A	-49.68%	-27.32%	-18.85%	N/A

Latest SYRE, ADMA, ZLAB, and AKRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.97	-$0.86	+$0.11	-$0.86	N/A	N/A
8/7/2025	Q2 2025	ZLAB Zai Lab	-$0.37	-$0.37	N/A	-$0.37	$125.66 million	$109.98 million
8/6/2025	Q2 2025	ADMA ADMA Biologics	$0.14	$0.15	+$0.01	$0.14	$121.77 million	$121.98 million
8/5/2025	Q2 2025	SYRE Spyre Therapeutics	-$0.73	-$0.49	+$0.24	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.21	5.33	2.78
AKRO Akero Therapeutics	0.02	12.66	12.66
SYRE Spyre Therapeutics	N/A	6.49	6.49
ZLAB Zai Lab	N/A	3.12	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
AKRO Akero Therapeutics	N/A
SYRE Spyre Therapeutics	80.39%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
AKRO Akero Therapeutics	7.07%
SYRE Spyre Therapeutics	15.43%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.63 million	230.28 million	Optionable
AKRO Akero Therapeutics	30	79.99 million	74.33 million	Optionable
SYRE Spyre Therapeutics	73	60.40 million	51.08 million	Optionable
ZLAB Zai Lab	1,869	111.08 million	105.57 million	Optionable

SYRE, ADMA, ZLAB, and AKRO Headlines

Recent News About These Companies

Zai Lab (NASDAQ:ZLAB) Insider Sells $240,669.84 in Stock

2 hours ago | marketbeat.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Analysts

August 21 at 4:13 AM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Trading Down 5.9% on Insider Selling

August 21 at 2:17 AM | americanbankingnews.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells $50,933.96 in Stock

August 20 at 6:18 PM | marketbeat.com

MY.Alpha Management HK Advisors Ltd Purchases New Shares in Zai Lab Limited Unsponsored ADR $ZLAB

August 20 at 8:06 AM | marketbeat.com

Zai Lab Points up as Chinese Gov’t Okays Tumor Treatment

August 19 at 8:34 PM | baystreet.ca

Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer

August 19 at 7:30 AM | businesswire.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells 1,438 Shares of Stock

August 19 at 5:01 AM | insidertrades.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells 46,387 Shares of Stock

August 16, 2025 | marketbeat.com

Townsquare Capital LLC Purchases 20,346 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 16, 2025 | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Insider Sells 3,000 Shares of Stock

August 14, 2025 | marketbeat.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Sells $139,304.96 in Stock

August 14, 2025 | marketbeat.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du Sells 50,000 Shares

August 14, 2025 | marketbeat.com

Ying Du Sells 50,000 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock

August 14, 2025 | marketbeat.com

Zai Lab Establishes Oncology Scientific Advisory Board

August 13, 2025 | finance.yahoo.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Insider Rafael Amado Sells 3,000 Shares

August 13, 2025 | insidertrades.com

Zai Lab Ltd’s Earnings Call Highlights Growth and Profitability Path

August 13, 2025 | msn.com

US Bancorp DE Has $664,000 Stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 12, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Issues Quarterly Earnings Results

August 10, 2025 | marketbeat.com

Here's What Analysts Are Forecasting For Zai Lab Limited (NASDAQ:ZLAB) After Its Second-Quarter Results

August 10, 2025 | finance.yahoo.com

Connor Clark & Lunn Investment Management Ltd. Buys 167,285 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE, ADMA, ZLAB, and AKRO Company Descriptions

ADMA Biologics NASDAQ:ADMA

$17.10 -0.20 (-1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$16.98 -0.12 (-0.70%)

As of 06:35 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Akero Therapeutics NASDAQ:AKRO

$48.29 +0.34 (+0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$49.00 +0.70 (+1.46%)

As of 04:52 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Spyre Therapeutics NASDAQ:SYRE

$16.78 +0.43 (+2.63%)

Closing price 04:00 PM Eastern

Extended Trading

$17.15 +0.37 (+2.20%)

As of 04:35 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Zai Lab NASDAQ:ZLAB

$33.99 +0.49 (+1.46%)

Closing price 04:00 PM Eastern

Extended Trading

$33.98 -0.01 (-0.01%)

As of 06:15 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time